TAPROOT

TAPROOT HEALTH™ COMPANY FACT SHEET
UNITING ALL TO CURE THE ONE.

WHO WE ARE

Founded in 2018, Taproot Health is uniting all oncology stakeholders in launching the National Oncology Master Observational Trial, clinical network and database. The resulting, first-of-its-kind, transparent and open data marketplace, is fueled by a patient- and clinic-centric model of shared data and revenue. Taproot's data-as-a-service model employs proprietary methods and innovative technology.

WHAT WE DO

Taproot collects regulatory-grade real-world data from advanced cancer patients across the nation. By providing a single, comprehensive database of real-time genetics, treatments, outcomes and patient experience—shared by all industry stakeholders—Taproot accelerates the availability of new diagnostic testing and novel therapeutics. The goal and belief is that such data will steadily improve outcomes over time.

WHY WE DO IT

Cancer is too big a problem for any one group to solve. Our nation loses 1,600 lives each day to cancer. Vital oncology data that could help either does not exist, or it's buried in medical records, scattered in silos, or sold in private transactions that benefit the select few. With the Taproot marketplace—data can be fully shared—allowing maximum research impact.

HOW WE DO IT

We are launching the National Oncology Trial (and database), "The Master Registry of Oncology Outcomes Associated with Testing and Treatments (abbreviated as ROOT)." ROOT empowers clinicians and patients to identify, collect, and share the highest quality cancer data providing a more complete picture of cancer treatment, care and outcomes. ROOT collects patient data from community clinics, academic centers and cancer patients across the nation through a novel and proprietary data collection method known as the Master Observational Trial or MOT. The data from ROOT will be available in a transparent, patient and clinic-centric marketplace to benefit all stakeholders in cancer care.

HELPING PATIENTS

Traditionally, patients have been left out of the real-world data collection efforts. Many patients–especially those with end-stage cancers want to help–but they need to know how, and they want to be actively involved. With ROOT, patients are identified by their oncologist and are asked to participate in ROOT. They give permission (consent) for their data to be collected by their doctor and are also provided a simple app, where they can self-track symptoms, quality

of life and side effects in real-time. By sharing their day-to-day symptoms, side effects, mood, nutrition, exercise. and other factors, and having it tied together with the clinical data collected by their physicians, researchers get a much clearer idea of the success (or failure) of a treatment and can learn how to improve care for patients with similar cancers in the future. All data sharing is compliant with current privacy laws.

SUPPORTING ONCOLOGISTS

Taproot's network is built by oncologists, for oncologists. Physician time is protected by using simplified data-collection methods that seamlessly integrate with clinical workflows. Clinics are able to support the data collection through initial payments and shared revenue for any data licensed for research. They also will have access to the collected data and will be enabled to participate in additional trials that come directly from ROOT. This encourages more participation in research.

PARTNERING WITH INDUSTRY

ROOT data is licensed by pharmaceutical companies, manufacturers, labs, researchers and other organizations that need high quality data to help them advance cancer care. Additionally, the scientific rigor of ROOT can help researchers conduct more specific or complex studies and publish them in a shorter time frames.

For pharma, faster identification of patients for clinical trials can shorten drug development and time-to-market—resulting in better efficiency and cost savings. The ROOT database can help companies develop new hypothesis and then identify exact patients to populate clinical trials. Depending on the rarity of the cancer, this could shave years off the selection process.

IMPROVING REIMBURSEMENT

Before new testing or treatment is covered by an insurance company, they need evidence of clinical benefit. A rich database showing how patient diagnostics, treatment details and outcomes provides the necessary evidence to prove that a new test is clinically valuable, biologically sound and scientifically validated.

EXECUTIVE LEADERSHIP

Dane Dickson, MD, CEO and Founder
Rebecca Owens, President and Co-Founder
For a complete list of investigators and affiliations, see website.

HEADQUARTERS

343 East 4th Street N, Suite 209
Rexburg, Idaho 83440
info@taprootco.com

TAPROOT
The Root to Health is Data.

90001052002